Results 41 to 50 of about 37,789 (262)

Identification of amino acid residues in the MT-loop of MT1-MMP critical for its ability to cleave low-density lipoprotein receptor

Frontiers in Cardiovascular Medicine, 2022
Low-density lipoprotein receptor (LDLR) mediates clearance of plasma LDL cholesterol, preventing the development of atherosclerosis. We previously demonstrated that membrane type 1-matrix metalloproteinase (MT1-MMP) cleaves LDLR and exacerbates the ...
Maggie Wang, Adekunle Alabi, Hong-mei Gu, Govind Gill, Ziyang Zhang, Suha Jarad, Xiao-dan Xia, Xiao-dan Xia, Yishi Shen, Gui-qing Wang, Da-wei Zhang   +10 more
doaj   +1 more source

Engineered Microvascular Model of the Blood–Brain–Tumor Barrier Reveals Endothelial Remodeling in Diffuse Midline Glioma

Advanced Healthcare Materials, EarlyView.
We developed a patient‐derived, functional microfluidic model of the diffuse midline glioma (DMG) blood–brain–tumor barrier (BBTB) comprised of endothelial cells, astrocytes, pericytes, and tumor cells. The system forms perfusable microvasculature, reveals the BBTB retains vascular integrity, identifies DMG‐specific transcriptomic changes distinct from
Kimberly R. Bennett, Yann S. Vanrobaeys, Tessy Teboh, Zakiya Smith, Anderson Scott, Cynthia Hajal, Paula T. Hammond, Joelle P. Straehla   +7 more
wiley   +1 more source

Physiological expression of macrophage apoE in the artery wall reduces atherosclerosis in severely hyperlipidemic mice

Journal of Lipid Research, 2002
We have previously reported that the introduction of macrophage apoE into mice lacking both apoE and the LDL receptor (apoE−/−/LDLR−/−) through bone marrow transplantation (apoE+/+/LDLR−/−→apoE−/−/LDLR−/−) produces progressive accumulation of apoE in ...
Sergio Fazio, Vladimir R. Babaev, Michael E. Burleigh, Amy S. Major, Alyssa H. Hasty, MacRae F. Linton   +5 more
doaj   +1 more source

Plaque‐Hepatic Targeting Nanotherapy Disrupts the PCSK9‐LOX‐1 Axis to Suppress oxLDL in Atherosclerosis

Advanced Science, EarlyView.
Self‑amplifying PCSK9–LOX‑1 feedback axis drives atherosclerotic progression by promoting oxLDL generation and endothelial uptake. A dual‑targeting nanoplatform (siPCSK9@PEAL NPs‑aL) is constructed to simultaneously silence hepatic PCSK9 for lipid lowering and block plaque LOX‑1 for anti‑inflammation.
Yi Duan, Yijie Qiu, Yan Zhu, Quan Wang, Jiangtao Lin, Yourong Duan, Qi Wang, Yi Dong   +7 more
wiley   +1 more source

The E3 ubiquitin ligase c-IAP1 regulates PCSK9-mediated LDLR degradation: Linking the TNF-α pathway to cholesterol uptake [PDF]

, 2010
Proprotein convertase subtilisin/kexin type 9 (PCSK9), in addition to LDLR (low-density lipoprotein receptor) and APOB (apolipoprotein B), is one of three loci implicated in autosomal dominant hypercholesterolaemia (ADH)^1^.
Lizhi Liu, Weiming Xu
core  

Phase Separation of TRIM21 Modulates PTPN14 Stability to Drive Flow‐Dependent Endothelial Activation and Atherogenesis

Advanced Science, EarlyView.
Disturbed flow promotes the formation of TRIM21‐rich biomolecular droplets, which concentrate TRIM21 and PTPN14 and facilitate their SPRY‐FERM interaction (illustrated by the TRIM21 D355‐PTPN14 R132 salt bridge). This condensate‐driven proximity enables TRIM21 to catalyze K48‐linked polyubiquitination of PTPN14 at lysine 956, leading to proteasome ...
Xue He, Qiannan Ma, Xue Wang, Jiaxu Mang, Chufeng Li, Bingjun Wu, Liu Yao, Yequn Chen, Qiankun Bao, Yi Zhu, Jinlong He   +10 more
wiley   +1 more source

LDLR-targeted pigs.

, 2014
A. Gene targeting strategy. Wild-type LDLR exons 2–6 are shown as gray boxes. NeoR cassette is depicted in red, with the arrow showing the orientation relative to LDLR.
Christopher S. Rogers (545570), Jason T. Struzynski (545565), Frank A. Rohret (545568), Timothy C. Nichols (545569), Bryan T. Davis (545563), Elizabeth P. Merricks (545566), Judy A. Rohret (545564), Xiao-Jun Wang (321924), Dwight A. Bellinger (545567)   +8 more
core   +1 more source

Leu22_Leu23 Duplication at the Signal Peptide of PCSK9 Promotes Intracellular Degradation of LDLr and Autosomal Dominant Hypercholesterolemia [PDF]

, 2022
[Background] PCSK9 (Proprotein convertase subtilisin/kexin type 9) regulates LDL-C (low-density lipoprotein cholesterol) metabolism by targeting LDLr (LDL receptor) for lysosomal degradation.
Sánchez Hernández, Rosa María, Martín Plágaro, César Augusto, Cenarro, Ana, Civeira, Fernando, Martín, César, Civeira Murillo, Fernando, Benito-Vicente, Asier, Galicia García, Unai, Uribe, Kepa, Larrea-Sebal, Asier, Larrea Sebal, Asier, Calle, Xabier, Lambert, Gilles, Belloso Uribe, Kepa, Benito Vicente, Asier, Cenarro Lagunas, Ana, Galicia-García, Unai, Uribe, Kepa B., Larrea, Asier, Sánchez-Hernández, Rosa, Palacios, Lourdes, Sánchez-Hernández, Rosa M., Jebari Benslaiman, Shifa, Stef, Marianne, Jebari-Benslaiman, Shifa   +24 more
core   +1 more source

PCSK9 and LDLR degradation [PDF]

Current Opinion in Lipidology, 2014
Proprotein convertase subtilisin/kexin type-9 (PCSK9) binds to LDL receptor (LDLR) and targets it for lysosomal degradation in cells. Decreased hepatic clearance of plasma LDL-cholesterol is the primary gauge of PCSK9 activity in humans; however, PCSK9's evolutionary role may extend to other lipoprotein classes and processes.
openaire   +2 more sources

Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma

Advanced Science, EarlyView.
This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert, Christophe Nguyen, Sean Edward Dunn, Magali Gary‐Bobo, Jérôme Lacombe, Justin Moser, Frédéric Zenhausern, Jean‐Olivier Durand, Frédérique Cunin   +8 more
wiley   +1 more source